董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jacob Chacko | 男 | Independent Director | 47 | 13.50万美元 | 14.50 | 2026-01-05 |
| Nancy Miller Rich | 女 | Independent Director | 67 | 12.25万美元 | 13.50 | 2026-01-05 |
| Shawn Cline Tomasello | 女 | Independent Director | 67 | 13.25万美元 | 13.50 | 2026-01-05 |
| Susannah Gray | 女 | Independent Director | 66 | 13.50万美元 | 13.50 | 2026-01-05 |
| David Kirn | 男 | President,Director and Chief Executive Officer | 64 | 205.13万美元 | 260.19 | 2026-01-05 |
| Charles Theuer | 男 | Independent Director | 63 | 13.50万美元 | 19.04 | 2026-01-05 |
| Glenn Sblendorio | 男 | Director | -- | 未披露 | 0.44 | 2026-01-05 |
| John F. Milligan | 男 | Executive Chairman of the Board | 65 | 25.50万美元 | 56.56 | 2026-01-05 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David Kirn | 男 | President,Director and Chief Executive Officer | 64 | 205.13万美元 | 260.19 | 2026-01-05 |
| Kristian Humer | 男 | Chief Financial Officer and Principal Financial Officer | 51 | 399.09万美元 | 未持股 | 2026-01-05 |
| Robert Young Kim | -- | Chief Medical Officer | -- | 未披露 | 未持股 | 2026-01-05 |
| Noriyuki Kasahara | -- | Chief Scientific Officer | -- | 未披露 | 未持股 | 2026-01-05 |
| Scott Bizily | -- | Chief Legal Officer and Corporate Secretary | -- | 未披露 | 未持股 | 2026-01-05 |
| Ashoo Gupta | 男 | Principal Financial Officer and Principal Accounting Officer | 50 | 未披露 | 未持股 | 2026-01-05 |
| John F. Milligan | 男 | Executive Chairman of the Board | 65 | 25.50万美元 | 56.56 | 2026-01-05 |
董事简历
中英对照 | 中文 | 英文- Jacob Chacko
-
Jacob Chacko，担任首席财务官。2008年8月至2014年5月，他担任TPG Capital的副总裁；此前，他同时在UCLA获得医学博士学位，在Harvard University获得工商管理硕士学位。此前，他是管理咨询公司McKinsey & Company的副合伙人，服务于医疗保健行业的客户。他曾担任：RentPath、EnvisionRx的董事；Par Pharmaceutical的审计委员会顾问； IMS Health and Quintiles Transnational的董事会观察员。他在Oxford University获得经济与社会历史硕士学位，曾是该校的Marshall Scholar；在University of Southern California获得生物学士学位、老年学学士学位。
Jacob Chacko has served as a member of board of directors since March 2019. Dr. Chacko has served as Chief Executive Officer of ORIC Pharmaceuticals, Inc., a clinical-stage oncology company focused on discovery and development of novel therapies against treatment-resistant cancers, since May 2018. Prior to ORIC, Dr. Chacko served as Chief Financial Officer of Ignyta, Inc., a publicly traded precision oncology company, from May 2014 until February 2018 when Ignyta was acquired by Roche Holdings, Inc. Prior to Ignyta, Dr. Chacko was an investor at TPG Capital from August 2008 until May 2014. From 2002 until 2003 Dr. Chacko was a consultant serving healthcare clients at McKinsey & Company. Dr. Chacko currently serves on the board of directors of Turning Point Therapeutics, Inc., a publicly-traded biotechnology company, from November 2018. Dr. Chacko served on the board of directors of RentPath Inc., a digital media company, from 2011 until 2014 Envision Pharmaceutical Services, LLC from 2013 until 2014 Bonti, Inc., a biotechnology company, from February 2018 until October 2018 and the Packard Children's Health Alliance at the Lucile Packard Children's Hospital Stanford from 2013 until June 2017. Dr. Chacko currently chairs the Western Regional Selection Committee for the Marshall Scholarship. Dr. Chacko concurrently received his M.D. from the U.C. Los Angeles and his M.B.A. from Harvard Business School. Dr. Chacko received a M.Sc. from Oxford University as a Marshall Scholar. - Jacob Chacko，担任首席财务官。2008年8月至2014年5月，他担任TPG Capital的副总裁；此前，他同时在UCLA获得医学博士学位，在Harvard University获得工商管理硕士学位。此前，他是管理咨询公司McKinsey & Company的副合伙人，服务于医疗保健行业的客户。他曾担任：RentPath、EnvisionRx的董事；Par Pharmaceutical的审计委员会顾问； IMS Health and Quintiles Transnational的董事会观察员。他在Oxford University获得经济与社会历史硕士学位，曾是该校的Marshall Scholar；在University of Southern California获得生物学士学位、老年学学士学位。
- Jacob Chacko has served as a member of board of directors since March 2019. Dr. Chacko has served as Chief Executive Officer of ORIC Pharmaceuticals, Inc., a clinical-stage oncology company focused on discovery and development of novel therapies against treatment-resistant cancers, since May 2018. Prior to ORIC, Dr. Chacko served as Chief Financial Officer of Ignyta, Inc., a publicly traded precision oncology company, from May 2014 until February 2018 when Ignyta was acquired by Roche Holdings, Inc. Prior to Ignyta, Dr. Chacko was an investor at TPG Capital from August 2008 until May 2014. From 2002 until 2003 Dr. Chacko was a consultant serving healthcare clients at McKinsey & Company. Dr. Chacko currently serves on the board of directors of Turning Point Therapeutics, Inc., a publicly-traded biotechnology company, from November 2018. Dr. Chacko served on the board of directors of RentPath Inc., a digital media company, from 2011 until 2014 Envision Pharmaceutical Services, LLC from 2013 until 2014 Bonti, Inc., a biotechnology company, from February 2018 until October 2018 and the Packard Children's Health Alliance at the Lucile Packard Children's Hospital Stanford from 2013 until June 2017. Dr. Chacko currently chairs the Western Regional Selection Committee for the Marshall Scholarship. Dr. Chacko concurrently received his M.D. from the U.C. Los Angeles and his M.B.A. from Harvard Business School. Dr. Chacko received a M.Sc. from Oxford University as a Marshall Scholar.
- Nancy Miller Rich
-
Nancy Miller Rich自2020年11月以来一直担任我们的董事会成员。她自2017年9月起担任多家制药和生物技术公司的顾问和顾问。此前，米勒-里奇曾在默克制药公司担任过多个领导职务，在两家公司合并之前，她曾在Schering-PloughCorporation担任过多个领导职务，包括最近担任高级副总裁，全球人类健康业务开发与许可部门的职务，2013年11月至2017年9月提供战略和商业支持，2007年1月至2013年11月担任集团Vice President，Consumer Care Global New Ventures和战略商业开发。1990年加入Schering-Plough之前，Miller-Rich在Sandoz Pharmaceuticals和Sterling Drug，Inc.担任多个商业和营销职位。Miller-Rich女士曾担任多家上市生物技术公司的董事会成员，例如自2018年4月以来担任InterceptPharmaceuticals，Inc.董事，自2020年1月以来担任AldeyraTherapeutics，Inc.董事，自2020年10月以来担任KadmonHoldings，Inc.董事。她于1981年获得纽约伊萨卡学院（Ithaca College）的工商管理营销本科学位。
Nancy Miller Rich,worked for Schering-Plough Corporation, where she was Senior Vice President, Global Human Health Business Development & Licensing, Strategy and Commercial Support from 2013 to 2017 and Group Vice President, Consumer Care Global New Ventures and Strategic Commercial Development from 2007 to 2013. Prior to joining Schering-Plough in 1990, Ms. Miller-Rich served in a variety of commercial and marketing roles at Sandoz Pharmaceuticals and Sterling Drug, Inc. She is a director of 4D Molecular Therapeutics, Inc., and previously served as a director of Intercept Pharmaceuticals, Inc. and Kadmon Holdings. Ms. Miller-Rich also serves as a board member of a number of private and not-for-profit entities. Ms. Miller-Rich received her B.S. in Business Administration, Marketing from Ithaca College in Ithaca, New York. - Nancy Miller Rich自2020年11月以来一直担任我们的董事会成员。她自2017年9月起担任多家制药和生物技术公司的顾问和顾问。此前，米勒-里奇曾在默克制药公司担任过多个领导职务，在两家公司合并之前，她曾在Schering-PloughCorporation担任过多个领导职务，包括最近担任高级副总裁，全球人类健康业务开发与许可部门的职务，2013年11月至2017年9月提供战略和商业支持，2007年1月至2013年11月担任集团Vice President，Consumer Care Global New Ventures和战略商业开发。1990年加入Schering-Plough之前，Miller-Rich在Sandoz Pharmaceuticals和Sterling Drug，Inc.担任多个商业和营销职位。Miller-Rich女士曾担任多家上市生物技术公司的董事会成员，例如自2018年4月以来担任InterceptPharmaceuticals，Inc.董事，自2020年1月以来担任AldeyraTherapeutics，Inc.董事，自2020年10月以来担任KadmonHoldings，Inc.董事。她于1981年获得纽约伊萨卡学院（Ithaca College）的工商管理营销本科学位。
- Nancy Miller Rich,worked for Schering-Plough Corporation, where she was Senior Vice President, Global Human Health Business Development & Licensing, Strategy and Commercial Support from 2013 to 2017 and Group Vice President, Consumer Care Global New Ventures and Strategic Commercial Development from 2007 to 2013. Prior to joining Schering-Plough in 1990, Ms. Miller-Rich served in a variety of commercial and marketing roles at Sandoz Pharmaceuticals and Sterling Drug, Inc. She is a director of 4D Molecular Therapeutics, Inc., and previously served as a director of Intercept Pharmaceuticals, Inc. and Kadmon Holdings. Ms. Miller-Rich also serves as a board member of a number of private and not-for-profit entities. Ms. Miller-Rich received her B.S. in Business Administration, Marketing from Ithaca College in Ithaca, New York.
- Shawn Cline Tomasello
-
Shawn Cline Tomasello，于2018年7月11日被任命为董事会非执行董事。凭借在制药和生物技术行业超过30年的经验，Shawn Cline Tomasello拥有丰富的商业和交易经验。自2015年以来，Tomasello女士一直担任领先的免疫肿瘤细胞治疗公司Kite Pharma的首席商务官，在该公司2017年被吉利德科学以119亿美元收购的交易中，她发挥了关键作用。在此之前，她曾担任Pharmacyclics, Inc.的首席商务官，该公司于2015年被艾伯维公司（AbbVie，Inc.）以210亿美元收购。Tomasello女士此前曾担任新基医药公司的美洲、血液学和肿瘤学总裁，在那里她管理着超过40亿美元的产品收入，并在各种全球扩张和收购战略中发挥了重要作用。她还曾在基因泰克、辉瑞实验室、迈尔斯制药和宝洁担任重要职务。Tomasello女士目前在Gamida Cell和UroGen Pharma，Ltd、TCR2 Therapeutics、4D Molecular Therapeutics的董事会任职。她此前曾在Principia Biopharma董事会任职；被赛诺菲收购，Abeona Therapeutics辞职，被IPSen、SA收购的Clementia制药，Inc.以及被United Healthcare收购的Diplomat Specialty。她获得了默里州立大学的MBA学位和辛辛那提大学的市场营销学士学位。Gamida Cell董事（2019年起）、UroGen Pharma Ltd.董事（2019年起）、TCR2 Therapeutics Inc.董事（2021年起）、4D Molecular Therapeutics董事（2020年起）、被IPSen，SA收购的Clementia制药，Inc.董事。（2018-2019年），Diplomat Pharmacy,Inc.非执行董事（2015-2020年），Abeona Therapeutics, Inc.-2020年赛诺菲收购的Principia Biopharma，Inc.董事（2019-2020年）。
Shawn Cline Tomasello,Appointed to the Board as a Non-Executive Director on July 11 2018.With more than 30 years' experience in the pharmaceutical and biotech industries, Shawn Cline Tomasello has substantial commercial and transactional experience. Since 2015 Ms. Tomasello had been Chief Commercial Officer at leading immuno-oncology cell therapy company Kite Pharma, where she played a pivotal role in the company's acquisition in 2017 by Gilead Sciences for $11.9 billion. Prior to this she served as Chief Commercial Officer at Pharmacyclics, Inc., which was acquired in 2015 by AbbVie, Inc. for $21 billion. Ms. Tomasello previously was President of the Americas, Hematology and Oncology at Celgene Corporation where she managed over $4 billion in product revenues, and was instrumental in various global expansion and acquisition strategies. She has also held key positions at Genentech, Pfizer Laboratories, Miles Pharmaceuticals and Procter & Gamble. Ms. Tomasello currently serves on the Board of Directors of Gamida Cell, Ltd. and UroGen Pharma, Ltd, TCR2 Therapeutics, and 4D Molecular Therapeutics. She previously served on the board of Principia Biopharma; acquired by Sanofi, Abeona Therapeutics resigned, Clementia Pharmaceuticals, Inc. which was acquired by Ipsen, SA, and Diplomat Specialty which was acquired by United Healthcare. She received a MBA from Murray State University and a B.S. in Marketing from the University of Cincinnati. Director, Gamida Cell, Ltd. (since 2019),Director, UroGen Pharma, Ltd. (since 2019),Director, TCR2 Therapeutics Inc. (since 2021),Director, 4D Molecular Therapeutics (since 2020),Director, Clementia Pharmaceuticals, Inc. which was acquired by Ipsen, SA. (2018 - 2019),Non-Executive Director, Diplomat Pharmacy, Inc. (2015 - 2020),Director, Abeona Therapeutics, Inc. -2020 Principia Biopharma, Inc. which was acquired by Sanofi (2019-2020). - Shawn Cline Tomasello，于2018年7月11日被任命为董事会非执行董事。凭借在制药和生物技术行业超过30年的经验，Shawn Cline Tomasello拥有丰富的商业和交易经验。自2015年以来，Tomasello女士一直担任领先的免疫肿瘤细胞治疗公司Kite Pharma的首席商务官，在该公司2017年被吉利德科学以119亿美元收购的交易中，她发挥了关键作用。在此之前，她曾担任Pharmacyclics, Inc.的首席商务官，该公司于2015年被艾伯维公司（AbbVie，Inc.）以210亿美元收购。Tomasello女士此前曾担任新基医药公司的美洲、血液学和肿瘤学总裁，在那里她管理着超过40亿美元的产品收入，并在各种全球扩张和收购战略中发挥了重要作用。她还曾在基因泰克、辉瑞实验室、迈尔斯制药和宝洁担任重要职务。Tomasello女士目前在Gamida Cell和UroGen Pharma，Ltd、TCR2 Therapeutics、4D Molecular Therapeutics的董事会任职。她此前曾在Principia Biopharma董事会任职；被赛诺菲收购，Abeona Therapeutics辞职，被IPSen、SA收购的Clementia制药，Inc.以及被United Healthcare收购的Diplomat Specialty。她获得了默里州立大学的MBA学位和辛辛那提大学的市场营销学士学位。Gamida Cell董事（2019年起）、UroGen Pharma Ltd.董事（2019年起）、TCR2 Therapeutics Inc.董事（2021年起）、4D Molecular Therapeutics董事（2020年起）、被IPSen，SA收购的Clementia制药，Inc.董事。（2018-2019年），Diplomat Pharmacy,Inc.非执行董事（2015-2020年），Abeona Therapeutics, Inc.-2020年赛诺菲收购的Principia Biopharma，Inc.董事（2019-2020年）。
- Shawn Cline Tomasello,Appointed to the Board as a Non-Executive Director on July 11 2018.With more than 30 years' experience in the pharmaceutical and biotech industries, Shawn Cline Tomasello has substantial commercial and transactional experience. Since 2015 Ms. Tomasello had been Chief Commercial Officer at leading immuno-oncology cell therapy company Kite Pharma, where she played a pivotal role in the company's acquisition in 2017 by Gilead Sciences for $11.9 billion. Prior to this she served as Chief Commercial Officer at Pharmacyclics, Inc., which was acquired in 2015 by AbbVie, Inc. for $21 billion. Ms. Tomasello previously was President of the Americas, Hematology and Oncology at Celgene Corporation where she managed over $4 billion in product revenues, and was instrumental in various global expansion and acquisition strategies. She has also held key positions at Genentech, Pfizer Laboratories, Miles Pharmaceuticals and Procter & Gamble. Ms. Tomasello currently serves on the Board of Directors of Gamida Cell, Ltd. and UroGen Pharma, Ltd, TCR2 Therapeutics, and 4D Molecular Therapeutics. She previously served on the board of Principia Biopharma; acquired by Sanofi, Abeona Therapeutics resigned, Clementia Pharmaceuticals, Inc. which was acquired by Ipsen, SA, and Diplomat Specialty which was acquired by United Healthcare. She received a MBA from Murray State University and a B.S. in Marketing from the University of Cincinnati. Director, Gamida Cell, Ltd. (since 2019),Director, UroGen Pharma, Ltd. (since 2019),Director, TCR2 Therapeutics Inc. (since 2021),Director, 4D Molecular Therapeutics (since 2020),Director, Clementia Pharmaceuticals, Inc. which was acquired by Ipsen, SA. (2018 - 2019),Non-Executive Director, Diplomat Pharmacy, Inc. (2015 - 2020),Director, Abeona Therapeutics, Inc. -2020 Principia Biopharma, Inc. which was acquired by Sanofi (2019-2020).
- Susannah Gray
-
Susannah Gray自Maravai Lifesciences Holdings, Inc.于2020年11月首次公开发行股票以来，一直担任Maravai Lifesciences Holdings, Inc.审计委员会成员和主席，并自2022年10月起担任Maravai Lifesciences Holdings, Inc.的薪酬和领导力发展委员会成员。Gray女士目前还在生物技术公司4D Molecular Therapeutics，Inc.、生物技术公司AnaptysBio，Inc.和生物制药公司Theravance BioPharma，Inc.的董事会任职。Gray女士此前曾于2021年4月至2024年8月在生物技术公司Morphic Holding, Inc.（Morphic Therapeutic，Inc.的母公司）以及2021年5月至2022年3月（Apria，Inc.被Owens & Minor, Inc.收购）的医疗保健公司Apria, Inc.的董事会任职，当时Apria，Inc.被TERM2。Gray女士于2005年1月至2018年12月担任药品特许权使用费买方Royalty Pharma Management LLC（“Royalty Pharma”）的首席财务官之职。Gray女士于2018年12月晋升为财务和战略执行副总裁，于2019年9月从Royalty Pharma退休。在加入Royalty Pharma之前，Gray女士于2002年至2004年担任CIBC World Markets高收益集团覆盖医疗保健部门的董事总经理和高级分析师，此前还曾在美林证券和大通证券（摩根大通证券的前身）担任类似职务。Gray女士拥有哥伦比亚大学MBA学位和卫斯理大学社会研究学士学位。
Susannah Gray has served on the Board and as the Chair of Maravai Lifesciences Holdings, Inc.'s Audit Committee since Maravai Lifesciences Holdings, Inc.'s IPO in November 2020 and has served on Maravai Lifesciences Holdings, Inc.'s Compensation and Leadership Development Committee since October 2022. Ms. Gray also currently serves on the Board of Directors of 4D Molecular Therapeutics, Inc., a biotech company, AnaptysBio, Inc., a biotech company, and Theravance BioPharma, Inc., a biopharmaceutical company. Ms. Gray previously served on the Board of Directors of Morphic Holding, Inc. (the parent company of Morphic Therapeutic, Inc.), a biotech company, from April 2021 to August 2024 and Apria, Inc., a healthcare company, from May 2021 to March 2022, when Apria, Inc. was acquired by Owens & Minor, Inc. Ms. Gray served as the Chief Financial Officer of Royalty Pharma Management LLC ("Royalty Pharma"), a buyer of pharmaceutical royalties, from January 2005 to December 2018. Ms. Gray was promoted to Executive Vice President of Finance and Strategy in December 2018 and retired from Royalty Pharma in September 2019. Prior to Royalty Pharma, Ms. Gray served as a managing director and senior analyst covering the healthcare sector of CIBC World Markets' high yield group from 2002 to 2004, and also previously served in similar roles at Merrill Lynch and Chase Securities (predecessor of J.P. Morgan Securities). Ms. Gray holds an MBA from Columbia University and a BA in Social Studies from Wesleyan University. - Susannah Gray自Maravai Lifesciences Holdings, Inc.于2020年11月首次公开发行股票以来，一直担任Maravai Lifesciences Holdings, Inc.审计委员会成员和主席，并自2022年10月起担任Maravai Lifesciences Holdings, Inc.的薪酬和领导力发展委员会成员。Gray女士目前还在生物技术公司4D Molecular Therapeutics，Inc.、生物技术公司AnaptysBio，Inc.和生物制药公司Theravance BioPharma，Inc.的董事会任职。Gray女士此前曾于2021年4月至2024年8月在生物技术公司Morphic Holding, Inc.（Morphic Therapeutic，Inc.的母公司）以及2021年5月至2022年3月（Apria，Inc.被Owens & Minor, Inc.收购）的医疗保健公司Apria, Inc.的董事会任职，当时Apria，Inc.被TERM2。Gray女士于2005年1月至2018年12月担任药品特许权使用费买方Royalty Pharma Management LLC（“Royalty Pharma”）的首席财务官之职。Gray女士于2018年12月晋升为财务和战略执行副总裁，于2019年9月从Royalty Pharma退休。在加入Royalty Pharma之前，Gray女士于2002年至2004年担任CIBC World Markets高收益集团覆盖医疗保健部门的董事总经理和高级分析师，此前还曾在美林证券和大通证券（摩根大通证券的前身）担任类似职务。Gray女士拥有哥伦比亚大学MBA学位和卫斯理大学社会研究学士学位。
- Susannah Gray has served on the Board and as the Chair of Maravai Lifesciences Holdings, Inc.'s Audit Committee since Maravai Lifesciences Holdings, Inc.'s IPO in November 2020 and has served on Maravai Lifesciences Holdings, Inc.'s Compensation and Leadership Development Committee since October 2022. Ms. Gray also currently serves on the Board of Directors of 4D Molecular Therapeutics, Inc., a biotech company, AnaptysBio, Inc., a biotech company, and Theravance BioPharma, Inc., a biopharmaceutical company. Ms. Gray previously served on the Board of Directors of Morphic Holding, Inc. (the parent company of Morphic Therapeutic, Inc.), a biotech company, from April 2021 to August 2024 and Apria, Inc., a healthcare company, from May 2021 to March 2022, when Apria, Inc. was acquired by Owens & Minor, Inc. Ms. Gray served as the Chief Financial Officer of Royalty Pharma Management LLC ("Royalty Pharma"), a buyer of pharmaceutical royalties, from January 2005 to December 2018. Ms. Gray was promoted to Executive Vice President of Finance and Strategy in December 2018 and retired from Royalty Pharma in September 2019. Prior to Royalty Pharma, Ms. Gray served as a managing director and senior analyst covering the healthcare sector of CIBC World Markets' high yield group from 2002 to 2004, and also previously served in similar roles at Merrill Lynch and Chase Securities (predecessor of J.P. Morgan Securities). Ms. Gray holds an MBA from Columbia University and a BA in Social Studies from Wesleyan University.
- David Kirn
-
David Kirn是我们的联合创始人，自2013年我们成立以来一直担任我们的首席执行官并任职于我们的董事会。Kirn博士此前曾担任我们的董事会执行主席，直到2020年8月John Milligan博士担任该职位。Kirn博士是U.C.Berkeley的生物工程兼职教授。他此前曾担任Ignite Immunotherapy Inc.的董事会执行主席，在那里他曾担任联席创始人。他曾担任Onyx Pharmaceuticals公司和Celgene公司的高级开发职务，也曾担任多种公司（包括Biogen Idec公司、Novartis公司、Cell Genesys公司、Pfizer公司和Bayer公司）的病毒载体基因疗法和癌症免疫疗法高级顾问10年以上。Kirn博士获得生理学学士学位，1985年获得加州大学伯克利分校Phi Beta Kappa博士学位，1989年获得旧金山大学医学院医学博士学位（Alpha Omega Alpha），并在哈佛医学院完成内科住院医师培训，Brigham and Women&8217；s Hospital（包括在附属VA Hospital担任首席医疗住院医师的任期）。他还在旧金山大学（U.C.San Francisco）完成了血液肿瘤学和临床研究奖学金，并在伯克利大学（U.C.Berkeley）的哈斯商学院（Haas Business School）完成了业务卓越证书。2013年，他获得强生创新中心颁发的强生公司企业家创新奖。
David Kirn is co-founder and has served as Chief Executive Officer and served on board of directors since inception in 2013. Dr. Kirn previously served as the Executive Chairman of board until August 2020 when John Milligan, Ph.D. assumed the position. Dr. Kirn is an Adjunct Professor of Bioengineering at U.C. Berkeley. He previously served as Executive Chairman of the board of Ignite Immunotherapy Inc., where he was a co-founder. Dr. Kirn held senior development positions at Onyx Pharmaceuticals and Celgene, and he was a senior advisor on viral vector gene therapeutics and cancer immunotherapy for over 10 years with numerous companies, including Biogen Idec, Novartis, Cell Genesys, Pfizer and Bayer. Dr. Kirn received a B.A. in Physiology Departmental Citation; Phi Beta Kappa from U.C. Berkeley in 1985 an M.D. (Alpha Omega Alpha) from U.C. San Francisco Medical School in 1989 and completed internal medicine residency training at Harvard Medical School, Brigham and Women's Hospital (including a term as Chief Medical Resident at affiliated VA hospital). He has also completed hematology-oncology and clinical research fellowships at U.C. San Francisco and completed a certificate of business excellence from the Haas Business School at U.C. Berkeley. In 2013 he was awarded the Johnson & Johnson Entrepreneur Innovator award from the J&J Innovation Center. - David Kirn是我们的联合创始人，自2013年我们成立以来一直担任我们的首席执行官并任职于我们的董事会。Kirn博士此前曾担任我们的董事会执行主席，直到2020年8月John Milligan博士担任该职位。Kirn博士是U.C.Berkeley的生物工程兼职教授。他此前曾担任Ignite Immunotherapy Inc.的董事会执行主席，在那里他曾担任联席创始人。他曾担任Onyx Pharmaceuticals公司和Celgene公司的高级开发职务，也曾担任多种公司（包括Biogen Idec公司、Novartis公司、Cell Genesys公司、Pfizer公司和Bayer公司）的病毒载体基因疗法和癌症免疫疗法高级顾问10年以上。Kirn博士获得生理学学士学位，1985年获得加州大学伯克利分校Phi Beta Kappa博士学位，1989年获得旧金山大学医学院医学博士学位（Alpha Omega Alpha），并在哈佛医学院完成内科住院医师培训，Brigham and Women&8217；s Hospital（包括在附属VA Hospital担任首席医疗住院医师的任期）。他还在旧金山大学（U.C.San Francisco）完成了血液肿瘤学和临床研究奖学金，并在伯克利大学（U.C.Berkeley）的哈斯商学院（Haas Business School）完成了业务卓越证书。2013年，他获得强生创新中心颁发的强生公司企业家创新奖。
- David Kirn is co-founder and has served as Chief Executive Officer and served on board of directors since inception in 2013. Dr. Kirn previously served as the Executive Chairman of board until August 2020 when John Milligan, Ph.D. assumed the position. Dr. Kirn is an Adjunct Professor of Bioengineering at U.C. Berkeley. He previously served as Executive Chairman of the board of Ignite Immunotherapy Inc., where he was a co-founder. Dr. Kirn held senior development positions at Onyx Pharmaceuticals and Celgene, and he was a senior advisor on viral vector gene therapeutics and cancer immunotherapy for over 10 years with numerous companies, including Biogen Idec, Novartis, Cell Genesys, Pfizer and Bayer. Dr. Kirn received a B.A. in Physiology Departmental Citation; Phi Beta Kappa from U.C. Berkeley in 1985 an M.D. (Alpha Omega Alpha) from U.C. San Francisco Medical School in 1989 and completed internal medicine residency training at Harvard Medical School, Brigham and Women's Hospital (including a term as Chief Medical Resident at affiliated VA hospital). He has also completed hematology-oncology and clinical research fellowships at U.C. San Francisco and completed a certificate of business excellence from the Haas Business School at U.C. Berkeley. In 2013 he was awarded the Johnson & Johnson Entrepreneur Innovator award from the J&J Innovation Center.
- Charles Theuer
-
Charles Theuer，2015年12月起，担任本公司董事。Theuer博士自2006年6月以来一直担任Tracon制药公司的总裁兼首席执行官。他此前曾担任Targegen，Inc.的首席医疗官，直到2006年6月。他目前任职于以下上市公司的董事会:Tracon Pharmaceuticals Inc.（2006年6月以来）和Oncternal Therapeutics Inc.（2018年5月以来），在那里他任职于科学与发展以及提名和公司治理委员会。Theuer博士于1985年获得麻省理工学院（Massachusetts Institute of Technology）的生命科学学士学位。他于1989年获得U.C.San Francisco的医学博士学位。他于2002年获得U.C.Irvine的环境健康科学博士学位。
Charles Theuer has served as a member of board of directors since December 2015. Dr. Theuer has served as President and Chief Executive Officer at Tracon Pharmaceuticals, Inc., since June 2006. He previously served as Chief Medical Officer at TargeGen, Inc. until June 2006. He currently serves on the board of directors of the following publicly-held companies: Tracon Pharmaceuticals Inc., since June 2006 and Oncternal Therapeutics Inc. since May 2018 where he serves on the Science and Development and Nominating and Corporate Governance committees. Dr. Theuer received a B.S. in Life Sciences from the Massachusetts Institute of Technology in 1985. He received his M.D. from U.C. San Francisco in 1989. He received his Ph.D. in Environmental Health Science from U.C. Irvine in 2002. - Charles Theuer，2015年12月起，担任本公司董事。Theuer博士自2006年6月以来一直担任Tracon制药公司的总裁兼首席执行官。他此前曾担任Targegen，Inc.的首席医疗官，直到2006年6月。他目前任职于以下上市公司的董事会:Tracon Pharmaceuticals Inc.（2006年6月以来）和Oncternal Therapeutics Inc.（2018年5月以来），在那里他任职于科学与发展以及提名和公司治理委员会。Theuer博士于1985年获得麻省理工学院（Massachusetts Institute of Technology）的生命科学学士学位。他于1989年获得U.C.San Francisco的医学博士学位。他于2002年获得U.C.Irvine的环境健康科学博士学位。
- Charles Theuer has served as a member of board of directors since December 2015. Dr. Theuer has served as President and Chief Executive Officer at Tracon Pharmaceuticals, Inc., since June 2006. He previously served as Chief Medical Officer at TargeGen, Inc. until June 2006. He currently serves on the board of directors of the following publicly-held companies: Tracon Pharmaceuticals Inc., since June 2006 and Oncternal Therapeutics Inc. since May 2018 where he serves on the Science and Development and Nominating and Corporate Governance committees. Dr. Theuer received a B.S. in Life Sciences from the Massachusetts Institute of Technology in 1985. He received his M.D. from U.C. San Francisco in 1989. He received his Ph.D. in Environmental Health Science from U.C. Irvine in 2002.
- Glenn Sblendorio
-
Glenn Sblendorio，最近的一位是从2017年7月到2023年7月被Astellas Pharma，Inc.收购的生物制药公司IVERIC bio，Inc.的首席执行官和董事会成员。在加入IVERIC之前，Sblendorio先生于2006年3月至2016年3月期间担任The Medicines Company的总裁兼首席财务官，并于2011年7月至2015年12月31日期间担任药品公司的董事会成员。在加入The Medicines Company之前，Sblendorio先生于2002年2月起担任Eyetech Pharmaceuticals，Inc.的执行副总裁兼首席财务官，直到该公司于2005年11月被OSI Pharmaceuticals，Inc.收购。此外，从1998年到2000年，Sblendorio先生担任MPM Capital Advisors的董事总经理。Sblendorio先生目前担任Mineralys Therapeutics，Inc.的董事会主席和Amicus Therapeutics, Inc.的董事会成员。此前，他曾担任Intercept制药，Inc.的董事会成员，直到2023年11月该公司被收购。Sblendorio先生在佩斯大学获得了学士学位，在费尔利·迪金森大学获得了工商管理硕士学位，并且毕业于哈佛大学高级管理课程。
Glenn Sblendorio,most recently was Chief Executive Officer and member of the Board of Directors of IVERIC bio, Inc., a biopharmaceutical company, from July 2017 to its acquisition by Astellas Pharma, Inc. in July 2023. Prior to IVERIC, Mr. Sblendorio was President and Chief Financial Officer of The Medicines Company from March 2006 through March 2016 and was a member of the Board of Directors of the Medicines Company from July 2011 through December 31, 2015. Before joining The Medicines Company, Mr. Sblendorio was Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc. from February 2002 until it was acquired by OSI Pharmaceuticals, Inc. in November 2005. In addition, from 1998 through 2000, Mr. Sblendorio served as a Managing Director of MPM Capital Advisors. Mr. Sblendorio currently serves as Chair of the Board of Directors of Mineralys Therapeutics, Inc. and a member of the Board of Directors of Amicus Therapeutics, Inc. Previously, he served as a member of the Board of Directors of Intercept Pharmaceuticals, Inc. until it was acquired in November 2023. Mr. Sblendorio received his B.B.A. from Pace University, his M.B.A. from Fairleigh Dickinson University and is a graduate of the Harvard Advanced Management Program. - Glenn Sblendorio，最近的一位是从2017年7月到2023年7月被Astellas Pharma，Inc.收购的生物制药公司IVERIC bio，Inc.的首席执行官和董事会成员。在加入IVERIC之前，Sblendorio先生于2006年3月至2016年3月期间担任The Medicines Company的总裁兼首席财务官，并于2011年7月至2015年12月31日期间担任药品公司的董事会成员。在加入The Medicines Company之前，Sblendorio先生于2002年2月起担任Eyetech Pharmaceuticals，Inc.的执行副总裁兼首席财务官，直到该公司于2005年11月被OSI Pharmaceuticals，Inc.收购。此外，从1998年到2000年，Sblendorio先生担任MPM Capital Advisors的董事总经理。Sblendorio先生目前担任Mineralys Therapeutics，Inc.的董事会主席和Amicus Therapeutics, Inc.的董事会成员。此前，他曾担任Intercept制药，Inc.的董事会成员，直到2023年11月该公司被收购。Sblendorio先生在佩斯大学获得了学士学位，在费尔利·迪金森大学获得了工商管理硕士学位，并且毕业于哈佛大学高级管理课程。
- Glenn Sblendorio,most recently was Chief Executive Officer and member of the Board of Directors of IVERIC bio, Inc., a biopharmaceutical company, from July 2017 to its acquisition by Astellas Pharma, Inc. in July 2023. Prior to IVERIC, Mr. Sblendorio was President and Chief Financial Officer of The Medicines Company from March 2006 through March 2016 and was a member of the Board of Directors of the Medicines Company from July 2011 through December 31, 2015. Before joining The Medicines Company, Mr. Sblendorio was Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc. from February 2002 until it was acquired by OSI Pharmaceuticals, Inc. in November 2005. In addition, from 1998 through 2000, Mr. Sblendorio served as a Managing Director of MPM Capital Advisors. Mr. Sblendorio currently serves as Chair of the Board of Directors of Mineralys Therapeutics, Inc. and a member of the Board of Directors of Amicus Therapeutics, Inc. Previously, he served as a member of the Board of Directors of Intercept Pharmaceuticals, Inc. until it was acquired in November 2023. Mr. Sblendorio received his B.B.A. from Pace University, his M.B.A. from Fairleigh Dickinson University and is a graduate of the Harvard Advanced Management Program.
- John F. Milligan
-
John F. Milligan，自2020年8月起担任董事会执行主席。Milligan博士此前分别于2008年5月和2016年3月至2019年2月担任Gilead Sciences， Inc.的总裁兼首席执行官，自1990年以来在Gilead担任了29年的各种职务。在加入Gilead之前，Milligan博士是加州大学旧金山医学中心的博士后研究员。Milligan博士自2013年7月起担任Pacific Biosciences of California董事会成员，也担任Ohio Wesleyan University董事会主席。他于1983年获得Ohio Wesleyan大学的化学学士学位，并于1988年获得Illinois大学Urbana-Champaign分校的博士学位。
John F. Milligan has served as a member of Kailera Therapeutics, Inc.'s board of directors since September 2024. Dr. Milligan previously served as the president and chief executive officer of Gilead Sciences, Inc. (NYSE: GILD), a biopharmaceutical company, from May 2008 and March 2016, respectively, until March 2019, and spent over 29 years at Gilead in various roles since 1990. Prior to joining Gilead, Dr. Milligan was a postdoctoral research fellow at the University of California San Francisco Medical Center. Dr. Milligan has served as executive chair of the board of directors of 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT) since August 2020 and as a director of PacBio, Inc. (Nasdaq: PACB) since July 2014 and chair of the board since September 2020. Dr. Milligan has served as a director at TurnCare, Inc. since January 2024. Dr. Milligan holds a B.A. in chemistry from Ohio Wesleyan University and a Ph.D. from the University of Illinois at Urbana Champaign. - John F. Milligan，自2020年8月起担任董事会执行主席。Milligan博士此前分别于2008年5月和2016年3月至2019年2月担任Gilead Sciences， Inc.的总裁兼首席执行官，自1990年以来在Gilead担任了29年的各种职务。在加入Gilead之前，Milligan博士是加州大学旧金山医学中心的博士后研究员。Milligan博士自2013年7月起担任Pacific Biosciences of California董事会成员，也担任Ohio Wesleyan University董事会主席。他于1983年获得Ohio Wesleyan大学的化学学士学位，并于1988年获得Illinois大学Urbana-Champaign分校的博士学位。
- John F. Milligan has served as a member of Kailera Therapeutics, Inc.'s board of directors since September 2024. Dr. Milligan previously served as the president and chief executive officer of Gilead Sciences, Inc. (NYSE: GILD), a biopharmaceutical company, from May 2008 and March 2016, respectively, until March 2019, and spent over 29 years at Gilead in various roles since 1990. Prior to joining Gilead, Dr. Milligan was a postdoctoral research fellow at the University of California San Francisco Medical Center. Dr. Milligan has served as executive chair of the board of directors of 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT) since August 2020 and as a director of PacBio, Inc. (Nasdaq: PACB) since July 2014 and chair of the board since September 2020. Dr. Milligan has served as a director at TurnCare, Inc. since January 2024. Dr. Milligan holds a B.A. in chemistry from Ohio Wesleyan University and a Ph.D. from the University of Illinois at Urbana Champaign.
高管简历
中英对照 | 中文 | 英文- David Kirn
David Kirn是我们的联合创始人，自2013年我们成立以来一直担任我们的首席执行官并任职于我们的董事会。Kirn博士此前曾担任我们的董事会执行主席，直到2020年8月John Milligan博士担任该职位。Kirn博士是U.C.Berkeley的生物工程兼职教授。他此前曾担任Ignite Immunotherapy Inc.的董事会执行主席，在那里他曾担任联席创始人。他曾担任Onyx Pharmaceuticals公司和Celgene公司的高级开发职务，也曾担任多种公司（包括Biogen Idec公司、Novartis公司、Cell Genesys公司、Pfizer公司和Bayer公司）的病毒载体基因疗法和癌症免疫疗法高级顾问10年以上。Kirn博士获得生理学学士学位，1985年获得加州大学伯克利分校Phi Beta Kappa博士学位，1989年获得旧金山大学医学院医学博士学位（Alpha Omega Alpha），并在哈佛医学院完成内科住院医师培训，Brigham and Women&8217；s Hospital（包括在附属VA Hospital担任首席医疗住院医师的任期）。他还在旧金山大学（U.C.San Francisco）完成了血液肿瘤学和临床研究奖学金，并在伯克利大学（U.C.Berkeley）的哈斯商学院（Haas Business School）完成了业务卓越证书。2013年，他获得强生创新中心颁发的强生公司企业家创新奖。
David Kirn is co-founder and has served as Chief Executive Officer and served on board of directors since inception in 2013. Dr. Kirn previously served as the Executive Chairman of board until August 2020 when John Milligan, Ph.D. assumed the position. Dr. Kirn is an Adjunct Professor of Bioengineering at U.C. Berkeley. He previously served as Executive Chairman of the board of Ignite Immunotherapy Inc., where he was a co-founder. Dr. Kirn held senior development positions at Onyx Pharmaceuticals and Celgene, and he was a senior advisor on viral vector gene therapeutics and cancer immunotherapy for over 10 years with numerous companies, including Biogen Idec, Novartis, Cell Genesys, Pfizer and Bayer. Dr. Kirn received a B.A. in Physiology Departmental Citation; Phi Beta Kappa from U.C. Berkeley in 1985 an M.D. (Alpha Omega Alpha) from U.C. San Francisco Medical School in 1989 and completed internal medicine residency training at Harvard Medical School, Brigham and Women's Hospital (including a term as Chief Medical Resident at affiliated VA hospital). He has also completed hematology-oncology and clinical research fellowships at U.C. San Francisco and completed a certificate of business excellence from the Haas Business School at U.C. Berkeley. In 2013 he was awarded the Johnson & Johnson Entrepreneur Innovator award from the J&J Innovation Center.- David Kirn是我们的联合创始人，自2013年我们成立以来一直担任我们的首席执行官并任职于我们的董事会。Kirn博士此前曾担任我们的董事会执行主席，直到2020年8月John Milligan博士担任该职位。Kirn博士是U.C.Berkeley的生物工程兼职教授。他此前曾担任Ignite Immunotherapy Inc.的董事会执行主席，在那里他曾担任联席创始人。他曾担任Onyx Pharmaceuticals公司和Celgene公司的高级开发职务，也曾担任多种公司（包括Biogen Idec公司、Novartis公司、Cell Genesys公司、Pfizer公司和Bayer公司）的病毒载体基因疗法和癌症免疫疗法高级顾问10年以上。Kirn博士获得生理学学士学位，1985年获得加州大学伯克利分校Phi Beta Kappa博士学位，1989年获得旧金山大学医学院医学博士学位（Alpha Omega Alpha），并在哈佛医学院完成内科住院医师培训，Brigham and Women&8217；s Hospital（包括在附属VA Hospital担任首席医疗住院医师的任期）。他还在旧金山大学（U.C.San Francisco）完成了血液肿瘤学和临床研究奖学金，并在伯克利大学（U.C.Berkeley）的哈斯商学院（Haas Business School）完成了业务卓越证书。2013年，他获得强生创新中心颁发的强生公司企业家创新奖。
- David Kirn is co-founder and has served as Chief Executive Officer and served on board of directors since inception in 2013. Dr. Kirn previously served as the Executive Chairman of board until August 2020 when John Milligan, Ph.D. assumed the position. Dr. Kirn is an Adjunct Professor of Bioengineering at U.C. Berkeley. He previously served as Executive Chairman of the board of Ignite Immunotherapy Inc., where he was a co-founder. Dr. Kirn held senior development positions at Onyx Pharmaceuticals and Celgene, and he was a senior advisor on viral vector gene therapeutics and cancer immunotherapy for over 10 years with numerous companies, including Biogen Idec, Novartis, Cell Genesys, Pfizer and Bayer. Dr. Kirn received a B.A. in Physiology Departmental Citation; Phi Beta Kappa from U.C. Berkeley in 1985 an M.D. (Alpha Omega Alpha) from U.C. San Francisco Medical School in 1989 and completed internal medicine residency training at Harvard Medical School, Brigham and Women's Hospital (including a term as Chief Medical Resident at affiliated VA hospital). He has also completed hematology-oncology and clinical research fellowships at U.C. San Francisco and completed a certificate of business excellence from the Haas Business School at U.C. Berkeley. In 2013 he was awarded the Johnson & Johnson Entrepreneur Innovator award from the J&J Innovation Center.
- Kristian Humer
Kristian Humer自2021年7月起担任Faeth Therapeutics，Inc.董事会成员。Humer先生自2025年11月起担任TERMA Therapeutics，Inc.的首席财务官。在加入4D Molecular治疗公司之前，Humer先生于2024年4月至2025年11月期间担任Foghorn Therapeutics Inc.的首席财务官。在加入Foghorn之前，Humer先生于2021年7月至2023年9月担任Viridian Therapeutics Inc.的首席财务官和首席商务官。在加入Viridian之前，Humer先生曾于2017年至2021年7月在Citigroup Inc.担任全球医疗团队的银行、资本市场和咨询董事总经理，帮助领导该公司为中小型生物制药公司和精选大型制药公司提供的投资银行咨询业务。此前他曾在Citigroup Inc.担任多个职务，包括2014年至2016年担任医疗保健投资银行业务董事，2011年至2013年担任医疗保健投资银行业务副总裁，2010年担任医疗保健投资银行业务助理。在加入Citigroup Inc.之前，Humer先生于2007年至2009年期间担任雷曼兄弟公司全球医疗保健团队投资银行部门的副总裁兼助理。胡默先生的职业生涯始于在瑞银集团和美林证券（一家美国银行公司）的投资银行和私人银行部门担任越来越重要的职务。他在杜克大学Fuqua商学院获得MBA学位，在英国雷丁大学获得会计与经济学学士学位（荣誉）。
Kristian Humer has served as a member of Faeth Therapeutics, Inc.'s board of directors since July 2021. Mr. Humer has served as the Chief Financial Officer of 4D Molecular Therapeutics, Inc. since November 2025. Prior to joining 4D Molecular Therapeutics Mr. Humer served as the Chief Financial Officer of Foghorn Therapeutics Inc. from April 2024 to November 2025. Prior to Foghorn, Mr. Humer served as the Chief Financial Officer and Chief Business Officer of Viridian Therapeutics Inc. from July 2021 to September 2023. Prior to Viridian, Mr. Humer served as Managing Director of Banking, Capital Markets and Advisory for the Global Healthcare team at Citigroup Inc., from 2017 to July 2021, where he helped lead the firm's investment banking advisory engagements for small and mid sized biopharma and select large cap pharmaceutical companies. He previously served in a number of roles at Citigroup Inc., including Director, Healthcare Investment Banking from 2014 to 2016, Vice President, Healthcare Investment Banking from 2011 to 2013 and Associate, Healthcare Investment Banking in 2010. Prior to joining Citigroup Inc., Mr. Humer served as Vice President and Associate in the Investment Banking Division for the Global Healthcare team at Lehman Brothers, Inc. from 2007 to 2009. Mr. Humer started his career serving positions of increasing responsibility in the investment banking and private banking divisions of UBS AG and Merrill Lynch (a Bank of America company). He received an MBA from the Fuqua School of Business at Duke University and a B.A. (Hons) in Accounting & Economics from the University of Reading, United Kingdom.- Kristian Humer自2021年7月起担任Faeth Therapeutics，Inc.董事会成员。Humer先生自2025年11月起担任TERMA Therapeutics，Inc.的首席财务官。在加入4D Molecular治疗公司之前，Humer先生于2024年4月至2025年11月期间担任Foghorn Therapeutics Inc.的首席财务官。在加入Foghorn之前，Humer先生于2021年7月至2023年9月担任Viridian Therapeutics Inc.的首席财务官和首席商务官。在加入Viridian之前，Humer先生曾于2017年至2021年7月在Citigroup Inc.担任全球医疗团队的银行、资本市场和咨询董事总经理，帮助领导该公司为中小型生物制药公司和精选大型制药公司提供的投资银行咨询业务。此前他曾在Citigroup Inc.担任多个职务，包括2014年至2016年担任医疗保健投资银行业务董事，2011年至2013年担任医疗保健投资银行业务副总裁，2010年担任医疗保健投资银行业务助理。在加入Citigroup Inc.之前，Humer先生于2007年至2009年期间担任雷曼兄弟公司全球医疗保健团队投资银行部门的副总裁兼助理。胡默先生的职业生涯始于在瑞银集团和美林证券（一家美国银行公司）的投资银行和私人银行部门担任越来越重要的职务。他在杜克大学Fuqua商学院获得MBA学位，在英国雷丁大学获得会计与经济学学士学位（荣誉）。
- Kristian Humer has served as a member of Faeth Therapeutics, Inc.'s board of directors since July 2021. Mr. Humer has served as the Chief Financial Officer of 4D Molecular Therapeutics, Inc. since November 2025. Prior to joining 4D Molecular Therapeutics Mr. Humer served as the Chief Financial Officer of Foghorn Therapeutics Inc. from April 2024 to November 2025. Prior to Foghorn, Mr. Humer served as the Chief Financial Officer and Chief Business Officer of Viridian Therapeutics Inc. from July 2021 to September 2023. Prior to Viridian, Mr. Humer served as Managing Director of Banking, Capital Markets and Advisory for the Global Healthcare team at Citigroup Inc., from 2017 to July 2021, where he helped lead the firm's investment banking advisory engagements for small and mid sized biopharma and select large cap pharmaceutical companies. He previously served in a number of roles at Citigroup Inc., including Director, Healthcare Investment Banking from 2014 to 2016, Vice President, Healthcare Investment Banking from 2011 to 2013 and Associate, Healthcare Investment Banking in 2010. Prior to joining Citigroup Inc., Mr. Humer served as Vice President and Associate in the Investment Banking Division for the Global Healthcare team at Lehman Brothers, Inc. from 2007 to 2009. Mr. Humer started his career serving positions of increasing responsibility in the investment banking and private banking divisions of UBS AG and Merrill Lynch (a Bank of America company). He received an MBA from the Fuqua School of Business at Duke University and a B.A. (Hons) in Accounting & Economics from the University of Reading, United Kingdom.
- Robert Young Kim
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Noriyuki Kasahara
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Scott Bizily
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Ashoo Gupta
Ashoo Gupta，自2024年6月起担任公司副总裁、财务和财务总监。在加入公司之前，Gupta先生于2023年9月至2024年6月在临床阶段的生物制药公司Kyverna Therapeutics，Inc.担任财务副总裁和公司财务总监。自2019年3月至2023年6月，Gupta先生在生物制药公司Myovant Sciences公司担任会计执行董事和公司控制人。Gupta先生拥有孟买大学商学学士学位，是一名注册会计师。
Ashoo Gupta,has served as the Company's Vice President, Finance & Controller since June 2024. Prior to joining the Company, Mr. Gupta served as Vice President of Finance and Corporate Controller at Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, from September 2023 to June 2024. From March 2019 to June 2023, Mr. Gupta served as Executive Director of Accounting and Corporate Controller at Myovant Sciences, Inc., a biopharmaceutical company. Mr. Gupta holds a Bachelor of Commerce from University of Mumbai and is a Certified Public Accountant.- Ashoo Gupta，自2024年6月起担任公司副总裁、财务和财务总监。在加入公司之前，Gupta先生于2023年9月至2024年6月在临床阶段的生物制药公司Kyverna Therapeutics，Inc.担任财务副总裁和公司财务总监。自2019年3月至2023年6月，Gupta先生在生物制药公司Myovant Sciences公司担任会计执行董事和公司控制人。Gupta先生拥有孟买大学商学学士学位，是一名注册会计师。
- Ashoo Gupta,has served as the Company's Vice President, Finance & Controller since June 2024. Prior to joining the Company, Mr. Gupta served as Vice President of Finance and Corporate Controller at Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, from September 2023 to June 2024. From March 2019 to June 2023, Mr. Gupta served as Executive Director of Accounting and Corporate Controller at Myovant Sciences, Inc., a biopharmaceutical company. Mr. Gupta holds a Bachelor of Commerce from University of Mumbai and is a Certified Public Accountant.
- John F. Milligan
John F. Milligan，自2020年8月起担任董事会执行主席。Milligan博士此前分别于2008年5月和2016年3月至2019年2月担任Gilead Sciences， Inc.的总裁兼首席执行官，自1990年以来在Gilead担任了29年的各种职务。在加入Gilead之前，Milligan博士是加州大学旧金山医学中心的博士后研究员。Milligan博士自2013年7月起担任Pacific Biosciences of California董事会成员，也担任Ohio Wesleyan University董事会主席。他于1983年获得Ohio Wesleyan大学的化学学士学位，并于1988年获得Illinois大学Urbana-Champaign分校的博士学位。
John F. Milligan has served as a member of Kailera Therapeutics, Inc.'s board of directors since September 2024. Dr. Milligan previously served as the president and chief executive officer of Gilead Sciences, Inc. (NYSE: GILD), a biopharmaceutical company, from May 2008 and March 2016, respectively, until March 2019, and spent over 29 years at Gilead in various roles since 1990. Prior to joining Gilead, Dr. Milligan was a postdoctoral research fellow at the University of California San Francisco Medical Center. Dr. Milligan has served as executive chair of the board of directors of 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT) since August 2020 and as a director of PacBio, Inc. (Nasdaq: PACB) since July 2014 and chair of the board since September 2020. Dr. Milligan has served as a director at TurnCare, Inc. since January 2024. Dr. Milligan holds a B.A. in chemistry from Ohio Wesleyan University and a Ph.D. from the University of Illinois at Urbana Champaign.- John F. Milligan，自2020年8月起担任董事会执行主席。Milligan博士此前分别于2008年5月和2016年3月至2019年2月担任Gilead Sciences， Inc.的总裁兼首席执行官，自1990年以来在Gilead担任了29年的各种职务。在加入Gilead之前，Milligan博士是加州大学旧金山医学中心的博士后研究员。Milligan博士自2013年7月起担任Pacific Biosciences of California董事会成员，也担任Ohio Wesleyan University董事会主席。他于1983年获得Ohio Wesleyan大学的化学学士学位，并于1988年获得Illinois大学Urbana-Champaign分校的博士学位。
- John F. Milligan has served as a member of Kailera Therapeutics, Inc.'s board of directors since September 2024. Dr. Milligan previously served as the president and chief executive officer of Gilead Sciences, Inc. (NYSE: GILD), a biopharmaceutical company, from May 2008 and March 2016, respectively, until March 2019, and spent over 29 years at Gilead in various roles since 1990. Prior to joining Gilead, Dr. Milligan was a postdoctoral research fellow at the University of California San Francisco Medical Center. Dr. Milligan has served as executive chair of the board of directors of 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT) since August 2020 and as a director of PacBio, Inc. (Nasdaq: PACB) since July 2014 and chair of the board since September 2020. Dr. Milligan has served as a director at TurnCare, Inc. since January 2024. Dr. Milligan holds a B.A. in chemistry from Ohio Wesleyan University and a Ph.D. from the University of Illinois at Urbana Champaign.